TY - JOUR
T1 - Use of granulocyte colony-stimulating factor for fluorine-18- fluorodeoxyglucose labeling in human leukocytes
AU - Moon, Seung Hwan
AU - Lee, Ho Young
AU - Eo, Jae Seon
AU - Kim, Seog Gyun
AU - Shim, Hye Kyung
AU - Kwon, Hyun Woo
AU - Kim, Chulhan
AU - Kim, Yong Il
AU - Lee, Dong Soo
AU - Chung, June Key
AU - Lee, Myung Chul
PY - 2011/3
Y1 - 2011/3
N2 - OBJECTIVE: Insufficient labeling efficiency and poor retention of radioactivity are the considerable shortcomings of fluorine-18- fluorodeoxyglucose (18F-FDG) labeling in human leukocytes. This study was conducted toevaluate the feasibility of using granulocyte colony-stimulating factor (G-CSF) to improve 18F-FDG labeling in human leukocytes. METHODS: Leukocyte separation was performed using methods reported earlier. Separated leukocytes were preincubated with G-CSF or insulin at 37°C for 1 h. Afterpreincubation, labeling was performed with 18F-FDG (37-74 MBq) at 37°C for 30 min. Retained radioactivity was assessed at 1-4 h after labeling by the same method described in earlier reports. The viability of labeled leukocytes was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay. RESULTS: Labeling efficiency of leukocytes preincubated withG-CSF, G-CSF with insulin, insulin, and control leukocytes was 52.1±8.9%, 49.9±10.5%, 40.3±7.7%, and 40.3±6.0%, respectively. G-CSF significantly increased the labeling efficiency compared with insulin (P=0.005) and control (P=0.004). In leukocytes preincubated with G-CSF, 77.0±1.2%, and 59.0±1.8% of radioactivity was retained at 1 and 3 h after labeling. There was no significant difference in retained radioactivity compared with that of leukocytes with different treatment at all time points. Furthermore, no significant difference in viabilities among leukocytes with different treatments was observed. CONCLUSION: Use of G-CSF significantly improved 18F-FDG labeling efficiency without a significant effect on cell viability and retention of radioactivity.
AB - OBJECTIVE: Insufficient labeling efficiency and poor retention of radioactivity are the considerable shortcomings of fluorine-18- fluorodeoxyglucose (18F-FDG) labeling in human leukocytes. This study was conducted toevaluate the feasibility of using granulocyte colony-stimulating factor (G-CSF) to improve 18F-FDG labeling in human leukocytes. METHODS: Leukocyte separation was performed using methods reported earlier. Separated leukocytes were preincubated with G-CSF or insulin at 37°C for 1 h. Afterpreincubation, labeling was performed with 18F-FDG (37-74 MBq) at 37°C for 30 min. Retained radioactivity was assessed at 1-4 h after labeling by the same method described in earlier reports. The viability of labeled leukocytes was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay. RESULTS: Labeling efficiency of leukocytes preincubated withG-CSF, G-CSF with insulin, insulin, and control leukocytes was 52.1±8.9%, 49.9±10.5%, 40.3±7.7%, and 40.3±6.0%, respectively. G-CSF significantly increased the labeling efficiency compared with insulin (P=0.005) and control (P=0.004). In leukocytes preincubated with G-CSF, 77.0±1.2%, and 59.0±1.8% of radioactivity was retained at 1 and 3 h after labeling. There was no significant difference in retained radioactivity compared with that of leukocytes with different treatment at all time points. Furthermore, no significant difference in viabilities among leukocytes with different treatments was observed. CONCLUSION: Use of G-CSF significantly improved 18F-FDG labeling efficiency without a significant effect on cell viability and retention of radioactivity.
KW - fluorine-18-fluorodeoxyglucose
KW - granulocyte colony-stimulating factor
KW - insulin
KW - leukocyte
KW - positron emission tomography
UR - http://www.scopus.com/inward/record.url?scp=79451471846&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79451471846&partnerID=8YFLogxK
U2 - 10.1097/MNM.0b013e328342dea1
DO - 10.1097/MNM.0b013e328342dea1
M3 - Article
C2 - 21178645
AN - SCOPUS:79451471846
VL - 32
SP - 186
EP - 191
JO - Nuclear Medicine Communications
JF - Nuclear Medicine Communications
SN - 0143-3636
IS - 3
ER -